Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

Pharmacology, Toxicology and Pharmaceutical Science

• Non Insulin Dependent Diabetes Mellitus 100%
• Placebo 100%
• Tirzepatide 100%
• Adverse Event 16%
• Hemoglobin A1c 16%
• Incretin 8%
• Diarrhea 8%
• Nausea 8%
• Gastric Inhibitory Polypeptide 8%
• Glucagon Like Peptide 1 Receptor Agonist 8%
• Glycosylated Hemoglobin 8%

Keyphrases

• Improving Health Outcomes 8%
• Incretin-based Therapy 8%
• Estimand 8%
• Glucose-dependent Insulinotropic Polypeptide 8%